anti sdc4 primary antibody (Bio-Techne corporation)
Bio-Techne corporation is a verified supplier 
Bio-Techne corporation manufactures this product 
93
Structured Review
Bio-Techne corporation
anti sdc4 primary antibody
Anti Sdc4 Primary Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+syndecan-4+antibody/Human+Syndecan-4+Antibody/bio_rxiv__2023__12__18__572183-106-6-16
Average 93 stars, based on 11 article reviews
Anti Sdc4 Primary Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+syndecan-4+antibody/Human+Syndecan-4+Antibody/bio_rxiv__2023__12__18__572183-106-6-16
Average 93 stars, based on 11 article reviews
anti sdc4 primary antibody - by Bioz Stars,
2026-09
93/100 stars
Images
1) Product Images from "Inhibition of MMP 2&9 protects the endothelial glycocalyx and improves diastolic function in diabetic cardiomyopathy"
Article Title: Inhibition of MMP 2&9 protects the endothelial glycocalyx and improves diastolic function in diabetic cardiomyopathy
Journal: bioRxiv
doi: 10.1101/2023.12.18.572183
Figure Legend Snippet: Cells were pre-incubated with SB-3CT for 2 hours before being treated with TNF-α for 6 hours. (a) SDC4 cell surface expression. Fluorescence intensity was normalized to cell number (n=5 for all groups; control vs TNF-α, *p<0.05; TNF-α vs TNF-α + SB-3CT, **p<0.01; One-way ANOVA). (b) SDC4 mRNA expression (n=5 for all groups; Control vs TNF-α, ****p<0.0001; TNF-α vs TNF-α + SB-3CT, *P<0.05; One-way ANOVA). (c) SDC4 concentration in the conditioned media (n=4 for all groups; Control vs TNF-α, ***p<0.001; TNF-α vs TNF-α + SB-3CT, **p<0.01; One-way ANOVA). (d) GAG concentration in the conditioned media (n=4 for all groups; Control vs TNF-α, *p<0.05; TNF-α vs TNF-α + SB-3CT, **p<0.01; One-way ANOVA)
Techniques Used: Incubation, Expressing, Fluorescence, Concentration Assay
Figure Legend Snippet: (a) MMP9 mRNA expression (n=5 for both groups; *p<0.05; unpaired t test). (b) MMP9 activity in the conditioned media (n=5 for all groups; control vs TNF-α, *p<0.05; TNF-α vs TNF-α + SB-3CT, **p< 0.01; One-way ANOVA). (c) MMP9 mRNA expression from shRNA MMP9 cells (n=4 for both groups; **p<0.01; unpaired t test). (d) SDC4 mRNA expression (n=4 for all groups; scrambled control vs scrambled control + TNF-α, ****p<0.0001. Scrambled control + TNF-α vs shRNA MMP9 + TNF-α, **p<0.01; One-way ANOVA). No significant difference found between shRNA MMP9 and scrambled control (p=0.5). (e) SDC4 concentration in the conditioned media (n=4 for all groups; scrambled control vs scrambled control + TNF-α, ***p<0.001. Scrambled control + TNF-α vs shRNA MMP9 + TNF-α, *p<0.05)
Techniques Used: Expressing, Activity Assay, shRNA, Concentration Assay
Related Articles
Western Blot:Article Title: Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression Article Snippet: s were cultured as previously described ( 5 , 7 , 8 , 9 ). New cultures were reestablished from frozen stocks after a maximum of 3 to 4 months of passage, and all cultures were screened for mycoplasma approximately every 6 months by the Small Molecule Screening Facility in the University of Wisconsin Carbone Cancer Center using the Immunoprecipitation:Article Title: Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression Article Snippet: s were cultured as previously described ( 5 , 7 , 8 , 9 ). New cultures were reestablished from frozen stocks after a maximum of 3 to 4 months of passage, and all cultures were screened for mycoplasma approximately every 6 months by the Small Molecule Screening Facility in the University of Wisconsin Carbone Cancer Center using the |